E Fund Management Co. Ltd. Acquires 1,219 Shares of Novavax, Inc. (NASDAQ:NVAX)

E Fund Management Co. Ltd. increased its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,340 shares of the biopharmaceutical company’s stock after acquiring an additional 1,219 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Novavax were worth $204,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of NVAX. State Street Corp grew its position in shares of Novavax by 26.7% during the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after purchasing an additional 1,621,772 shares in the last quarter. Shah Capital Management boosted its stake in shares of Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock valued at $89,637,000 after buying an additional 1,333,305 shares during the period. Two Sigma Advisers LP grew its position in Novavax by 48.9% during the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock worth $25,252,000 after buying an additional 656,900 shares in the last quarter. Bank of Montreal Can grew its position in Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock worth $32,643,000 after buying an additional 517,727 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Novavax by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock worth $44,245,000 after acquiring an additional 304,159 shares during the period. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Stock Up 6.0 %

Novavax stock opened at $8.34 on Monday. The stock has a market cap of $1.34 billion, a PE ratio of -3.69, a P/E/G ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 12-month low of $3.81 and a 12-month high of $23.86. The business’s 50-day moving average price is $8.46 and its two-hundred day moving average price is $9.77.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same period last year, the firm posted ($1.44) earnings per share. As a group, analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director James F. Young sold 5,400 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the sale, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Rachel K. King sold 4,150 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares of the company’s stock, valued at $133,225.40. This represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,150 shares of company stock valued at $119,641. 1.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. BTIG Research assumed coverage on shares of Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 price objective for the company. Finally, TD Cowen raised shares of Novavax to a “hold” rating in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Novavax currently has an average rating of “Hold” and an average target price of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.